Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
June-2016 Volume 11 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2016 Volume 11 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells

  • Authors:
    • Na Li
    • Hongxing Wang
    • Jie Zhang
    • Erchen Zhao
  • View Affiliations / Copyright

    Affiliations: Department of Pathology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Clinical Immunology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
  • Pages: 3743-3748
    |
    Published online on: April 19, 2016
       https://doi.org/10.3892/ol.2016.4471
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Hypoxia inducible factors (HIFs) are important regulatory molecules of the intracellular oxygen-signaling pathway. The role of HIF-1α has been confirmed in breast carcinoma; however, little is understood concerning the function of HIF‑2α. The present study treated human breast adenocarcinoma MCF‑7 cells with the HIF activator cobalt chloride, and transfected HIF‑2α small interfering RNAs (siRNAs) into MCF‑7 cells to suppress HIF‑2α expression. The siRNAs significantly reduced the levels of HIF‑2α and matrix metalloproteinase (MMP)‑2 in the treated MCF‑7 cells. An invasion assay demonstrated that the siRNAs targeting HIF‑2α inhibited the invasion potency of the cells. The present study concludes that loss of HIF‑2α may be associated with a decreased risk for the progression of human breast cancer, due to the downregulation of the expression of MMP-2.

Introduction

Hypoxia inducible factors (HIFs) belong to the family of helix-loop-helix-PAS domain transcription factors (1,2). It has been demonstrated that there are ~150 HIF target genes (3). HIFs accelerate tumor progression and cell survival by regulating a wide variety genes that control various metabolic processes, including anaerobic metabolism (glucose transporter 1), angiogenesis (vascular endothelial growth factor), regulation of cell cycle and intracellular pH (carbonic anhydrase-9), response to DNA damage, alteration of the extracellular matrix and cell adhesion, migration, proliferation and apoptosis [p21, p27, matrix metalloproteinase (MMP)-2 and 9] (4–7). The HIF pathway in hypoxia is an important therapeutic target for reducing the size, metastatic potential and therapeutic resistance of the primary tumor (8).

There are three isoforms of the HIF-α subunit: HIF-1α, HIF-2α and HIF-3α. HIF-2 is dimerized by the HIF-1β subunit and HIF-2α subunit, and the stability and transcriptional activity of HIF-2α is accommodated by oxygen-dependent hydroxylation. In normoxic conditions, the α subunit is constitutively expressed but rapidly degraded. In a low-oxygen environment, the α subunit is stabilized and translocated to the nucleus (9,10). HIF-2α is regulated by fewer genes compared with HIF-1α; in breast adenocarcinoma MCF-7 cells, there are only a small group of hypoxia-associated genes that are associated with HIF-2α, while 80% of hypoxia-regulated genes are associated with HIF-1α, including vascular endothelial growth factor, erythropoietin and matrix metalloproteinases (11,12). Previous studies have confirmed that HIF-1 is associated with tumor progression in certain carcinomas, including breast, non-small cell lung and uterine cancer, and patients with high levels of HIF-1 have a poor response to cancer therapies (13–19). However, little is understood concerning the effect of HIF-2α in solid tumors. Previous studies have demonstrated that a cell's reaction to hypoxia is primarily regulated by HIF-1α in all cells, including breast carcinoma cells, but is regulated by HIF-2α in gastrointestinal epithelium, heart, kidney, and renal carcinoma cells (20).

RNA interference (RNAi) is a powerful mechanism for targeting post-transcriptional gene silencing, in which double-stranded RNA is successfully introduced into mammalian cells, which downregulates the expression of target genes or suppresses the replication and transcription of pathogens by degrading the homologous mRNA sequences (21). In the present study, synthesized small interfering (si) RNAs targeting the HIF-2α gene was transfected into breast adenocarcinoma MCF-7 cells using Lipofectamine® 2000 to knockdown the expression of the HIF-2α on a protein and mRNA level. Results from studies regarding the effect and impact of HIF-2α gene silencing on the cell growth and invasion potency may contribute to additional research on the HIF complex and its possible therapeutic applications. The present study investigated the correlation between HIF-2α and MMP-2 expression, and the significant role of HIF-2α in breast carcinoma cell survival and invasion.

Materials and methods

Cell lines and hypoxia treatment

The breast adenocarcinoma MCF-7 cell line was purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were cultured in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal calf serum (Invitrogen; Thermo Fisher Scientific, Inc.), streptomycin (100 U/ml; Thermo Fisher Scientific, Inc.) and penicillin (100 U/ml; Thermo Fisher Scientific, Inc.) at 37°C in 5% CO2. When the cells had reached 80% confluence, they were cultured with hypoxia-mimetic agent, cobalt chloride (CoCl2; Sigma-Aldrich, St. Louis, MO, USA) at various concentrations (50, 100 and 200 µmol/l) for at 37°C in 5% CO2 for 24 h. A maximum HIF-2α accumulation was reached at 100 µmol/l CoCl2; therefore, 100 µmol/l CoCl2 was selected for use as the standard concentration for subsequent experiments (Fig. 1).

Figure 1.

HIF-2α mRNA expression in human breast carcinoma MCF-7 cells. Lane 1, cells cultured under normoxic conditions (20% O2); lane 2, cells treated with 50 µmol/l CoCl2; lane 3, cells treated with 100 µmol/l CoCl2; lane 4, cells treated with 200 µmol/l CoCl2. The data are represented as the mean ± standard deviation. *P<0.05 vs. normoxic conditions. HIF-2α, hypoxia-inducible factor-2α; CoCl2, cobalt chloride; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

siRNAs and transfection

The HIF-2α siRNAs were designed according to the study by Meade et al (22) and were synthesized by Guangzhou Ruibo Biological Technology Co., Ltd. (Guangzhou, China) as follows: siRNA-1, sense 5′-GCAAAUGUACCCAAUGAUADTDT-3′ and antisense 5′-UAUCAUUGGGUACAUUUGCDTDT-3′; siRNA-2, sense 5′-CAGCAUCUUUGAUAGCAGUDTDT-3′ and antisense 5′-ACUGCUAUCAAAGAUGCUGDTDT-3′; negative control siRNA, sense 5′-CAGCAGGGUUGAUAGCAUGDTDT-3′ and antisense 5′-ACUGCCCCCAAAGAUGCUGDTDT-3æ. The MCF-7 cells were transfected with the siRNAs. Briefly, the cells were seeded into 24-well plates and cultured in RPMI-1640 medium for 24 h (at 37°C in 5% CO2) to reach 50–70% confluence. HIF-2α siRNA or the negative control siRNA were transfected into the cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The cells were placed in a normoxic or hypoxic atmosphere for 24 h following transfection. The experimental groups were as follows: Parental cell group, MCF-7 cells without CoCl2 treatment; control group, MCF-7 cells treated with 100 µmol/l CoCl2; hypoxia + RNAi 1 group, HIF-2α siRNA1-transfected MCF-7 cells treated with 100 µmol/l CoCl2; hypoxia + RNAi 2 group, HIF-2α siRNA2-transfected MCF-7 cells treated with 100 µmol/l CoCl2.

Reverse transcription polymerase chain reaction (PCR)

Total RNA was extracted from the cells using TRIzol reagent (Gibco®; Thermo Fisher Scientific, Inc.). The cDNA was synthesized from the RNA using the Reverse Transcription System (Promega Corporation, Madison, WI, USA), according to the manufacturer's protocol. The expressions of HIF-2α and MMP-2 were detected using the following primers: HIF-2α, forward 5′-TGAAAACAGAGTCCGAAGCC-3′ and reverse 5′-GTGGCTGACTTGAGGTTGA-3′; MMP-2, forward 5′-TTCAAGGACCGGTTCATTTGGCGGACTGTG-3′ and reverse 5′-TTCCAAACTTCACGCTCTTCAGACTTTGGTT-3′. The following glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were also used: forward, 5′-ATTCATCTCTCCTCTCCCA-3′ and reverse, 5′-GTTGGTGGTTGGTACTGT-3′. Primers were designed using the Primer Premier Software version 5 (Premier Biosoft International, Palo Alto, CA, USA) and synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). PCR was performed using the SYBR Premix Ex Taq II kit (Takara Biotechnology Co., Ltd., Dalian, China) and the ABI 9700 PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.), and under the following conditions: 94°C for 45 sec and 55°C for 1 min for 35 cycles, with an initial denaturation step at 72°C for 10 min. The PCR products were subjected to 1.5% agarose gel electrophoresis, with GAPDH (580 bp) as an internal control. PCR products were quantified with a TotalLab Quant Phoretix 1D Pro software software (TotalLab Ltd., Newcastle Upon Tyne, UK).

Western blotting analysis

Protein was extracted from the cells using NP-40 Lysis Buffer (Beyotime Institute of Biotechnology, Haimen, China). Protein concentration was determined using a bicinchoninic acid assay (Beyotime Institute of Biotechnology), according to the manufacturer's protocol. Total protein of breast carcinoma cells was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were displaced to polyvinylidene difluoride (PVDF) membranes by Pharmacia Phast gel electrophoresis system (Roche Diagnostics, Indianapolis, IN, USA). The PVDF membrane was blocked with 5% skim milk blocking buffer (Beyotime Institute of Biotechnology) for 1 h. The immunoblots were incubated with the following primary antibodies: Rabbit polyclonal anti-HIF-2α (dilution, 1:150; catalog no., ab73895; Abcam, Cambridge, UK); mouse monoclonal anti-MMP-2 (dilution, 1:500; catalog no., ab3158; Abcam); and mouse monoclonal anti-β-actin (dilution, 1:500; catalog no., ab6276; Abcam). Subsequently, the membranes were incubated at 4°C for 24 h with gentle agitation. After washing twice with phosphate-buffered saline, the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit (dilution, 1:1,000; catalog no., BA1054-1; BosterBio, Wuhan, China) and goat anti-mouse (dilution, 1:1,000; catalog no., BA1051; BosterBio) IgG secondary antibodies for 1 h at room temperature. After washing with PBS, the immuno-blotting signal was detected using a chemiluminescence system (ECL; Thermo Fisher Scientific, Inc.). The results were quantified using TotalLab version 2.0 software (Total Lab, Newcastle upon Tyne, UK). β-actin protein was used as an internal control.

Invasion assays

The invasion ability of the cells was detected using a Boyden chamber (BD Biosciences, Franklin Lakes, NJ, USA. For invasion assays, polycarbonate filters with 8-µm pore size (EMD Millipore, Billerica, MA, USA) were covered with Matrigel (Sigma-Aldrich), which was diluted to 1:20 with serum-free RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.). The polycarbonate filters were dried at room temperature for 24 h. In total, ~5×106 cells in 500 µl RPMI-1640 media were placed in the upper chamber and 400 µl RPMI-1640 medium was placed in the lower chamber. The cells were incubated at 37°C in 5% CO2 for 24 h. The cells on the bottom surface of the polycarbonate filter were removed and fixed in 4% glutaraldehyde solution and stained with hematoxylin and eosin (Enzyme-linked Biotechnology Co., Ltd., Shanghai, China). Invasive cells were counted using a microscope (magnification, ×400; BX51; Olympus Corp., Tokyo, Japan). The invasion index and the cell invasion inhibition rate were calculated as previously described (23). Briefly, the invasion index was defined as the number of cells that migrated through the 8-µm pores of the filter in the experimental group divided by the number of cells that migrated through the filter in the control group × 100. The cell invasion inhibition rate was equal to the number of cells that migrated through the filter in the control group minus the number of cells that migrated through the filter in the experimental group divided by the number of cells that migrated through the filter in the control group × 100.

Statistical analysis

The data are presented as the mean ± standard deviation. Experiments were performed in triplicate. All statistical analyses were performed using SPSS version 13.0 software (SPSS, Inc., Chicago, IL, USA). Independent sample t-test was used to determine the statistical significance between the means. P<0.05 was considered to indicate a statistically significant difference.

Results

Hypoxia mimetic CoCl2 specifically elevated HIF-2α mRNA levels

To investigate whether the expression of HIF-2α is regulated by a hypoxic environment, the mRNA levels of HIF-2α were compared in cells that were cultured under normoxic (20% O2) and hypoxia-mimetic (CoCl2) conditions. After a 24 h incubation, HIF-2α mRNA levels clearly increased in the cells that were treated with CoCl2 (100 µmol/l). It has been established that CoCl2 treatment can prevent oxygen signaling in cells, leading to chemical hypoxia. The results revealed that the hypoxic effect increased in severity as CoCl2 dose increased from 50 to 100 µmol/l. This indicates that CoCl2 induces hypoxia in a dose-dependent manner. In addition, the expression of HIF-2α also increased in a dose-dependent manner. Notably, the toxicity of CoCl2 increased in a dose-dependent manner and thus at high doses this led to severe hypoxia and subsequent cell death. As a result, the expression of HIF-2α was decreased. By contrast, normoxic conditions (20% O2) had only a slight effect on HIF-2α transcription (Fig. 1). De novo transcription of GAPDH was similar among treatment groups. These results suggest that exposure of CoCl2 (100 µmol/l) promoted HIF-2α transcription, evidenced by the increase in HIF-2α mRNA levels. A CoCl2 concentration of 100 µmol/l was used in all subsequent experiments.

Effects of HIF-2α knockdown on the expression of MMP-2 in MCF-7 cells

The association between HIF-2α expression and its target gene MMP-2 was analyzed in MCF-7 cells using siRNAs against HIF-2α. As expected, HIF-2α siRNA markedly reduced the mRNA and protein levels of the targeted HIF-2α subunit (Fig. 2). Subsequently, the effects of HIF-2α knockdown on CoCl2-mediated induction of MMP-2 expression was analyzed. As shown in Fig. 3, MMP-2 protein and mRNA levels were downregulated significantly in MCF-7 cells transfected with HIF-2α siRNA compared with the control group (P=0.033). Overall, these data demonstrated that hypoxia induces HIF-2α expression at mRNA and protein levels in MCF-7 cells, and HIF-2α siRNA inhibited MMP-2 expression in MCF-7 cells.

Figure 2.

Effects of HIF-2α knockdown on the expression of HIF-2α protein and mRNA in breast adenocarcinoma MCF-7 cells. Lane 1, cells cultured under normoxic conditions (20% O2); lane 2, cells treated with 50 µmol/l CoCl2; lane 3, cells treated with 100 µmol/l CoCl2; lane 4, cells treated with 200 µmol/l CoCl2. The data are represented as the mean ± standard deviation. *P<0.05 vs. parental cell group. HIF-2α, hypoxia-inducible factor-2α; siRNA, small interfering RNA; RNAi, RNA interference; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Figure 3.

Effects of HIF-2α knockdown on the expression of target gene MMP-2 protein and mRNA in breast adenocarcinoma MCF-7 cells. Lane 1, cells cultured under normoxic conditions (20% O2); lane 2, cells treated with 50 µmol/l CoCl2; lane 3, cells treated with 100 µmol/l CoCl2; lane 4, cells treated with 200 µmol/l CoCl2. The data are represented as the mean ± standard deviation. *P<0.05 vs. parental cell group. HIF-2α, hypoxia-inducible factor-2α; MMP, matrix metalloproteinase; siRNA, small interfering RNA; RNAi, RNA interference; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Effects of HIF-2α siRNAs on cancer cell invasion

The effects of HIF-2α siRNAs on cell migration were assessed using a Boyden chamber assay, which has been modified. As shown in Fig. 4, HIF-2α siRNA significantly inhibited cell migration compared with the control group (hypoxia + RNAi 1, P<0.006; hypoxia + RNAi 2, P=0.004). By contrast, the migratory ability of the control group cells were significantly increased compared with the hypoxia + RNAi groups (hypoxia + RNAi 1, P<0.006; hypoxia + RNAi 2, P=0.004) (Fig. 4). There was no difference on the migratory capabilities of the hypoxia + RNAi groups compared with the parental cell group (P=0.176). These data suggest that HIF-2α was a positive regulator for cell invasion and HIF-2α siRNA may inhibit the invasive capacity of MCF-7 cells (Table I).

Figure 4.

Suppression effects of hypoxia-inducible factor-2α small interfering RNA on the invasion potency of breast adenocarcinoma MCF-7 cells. Migrated cells were stained with hematoxylin and eosin from the (A) parental cell, (B) control, (C) hypoxia + RNAi 1 and (D) hypoxia + RNAi 2 groups. A significant reduction in the number of invaded cells indicated a decrease in the invasive potency of the treated cells. RNAi, RNA interference.

Table I.

Effects of HIF-2α small interfering RNA on the invasion potency of human breast adenocarcinoma MCF-7 cells.

Table I.

Effects of HIF-2α small interfering RNA on the invasion potency of human breast adenocarcinoma MCF-7 cells.

GroupNo. of cellsInvasion index, %Cell invasion inhibition rate, %
Parental cell   16.63±11.84a   59.06a40.94a
Control28.16±10.16100.00−
Hypoxia + RNAi 1   14.44±11.12a   51.28a48.72a
Hypoxia + RNAi 2   13.86±15.12a   49.22a50.78a

{ label (or @symbol) needed for fn[@id='tfn1-ol-0-0-4471'] } The data are presented as the mean ± standard deviation.

a P<0.05 vs. control group. HIF-2α, hypoxia inducible factor-2α; siRNA, small interfering RNA; RNAi, RNA interference.

Discussion

Hypoxia is common in numerous types of solid tumors, where tumor cells proliferate rapidly and form large solid tumor masses, leading to obstruction and compression of the blood vessels surrounding these masses. These abnormal blood vessels often do not function properly, resulting in a poor O2 supply to the center tumor regions. Tumor cells in this hypoxic region begin to adapt these low oxygen tension conditions by activating several survival pathways, including the HIF pathway (22,24,25). The responses of cells to hypoxia are mediated primarily through HIFs, which are critical mediators in the cellular and systemic hypoxia response to low oxygen levels via the accommodation of numerous genes that are induced by hypoxia (14,26–28). The activation of the HIF transcription factor is the most commonly identified pathway activated by hypoxic cells in harsh microenvironments. Activated HIFs exhibit a crucial role in adaptive responses of tumor cells to changes in O2 levels via transcriptional activation of >100 downstream genes which regulate vital biological processes required for tumor survival and progression. Examples include genes involved in glucose metabolism, cell proliferation, migration and angiogenesis (29). Currently, the role of HIF-2α in certain solid tumors is unclear.

The present study investigated the association and significance between the expression of HIF-2α and clinical features of breast carcinoma tissue. The author's previous histological studies have demonstrated that a higher expression of the HIF-2α protein is associated with breast cancer invasion and metastasis (30). The aim of the present study was to reveal whether HIF-2α has effects on the invasion potency of human breast carcinoma MCF-7 cells, and to reveal a possible mechanism for this function under hypoxia by using the RNAi method.

CoCl2 prevents HIF-1α from binding to prolyl hydroxylases, so that they are not hydroxylated and are subsequently degraded by proteasomes (31). CoCl2 has been used in in vivo and in vitro studies to generate hypoxia by inhibiting HIF-1 specific prolyl-hydroxylase and occupying its iron-binding site, leading to impaired binding of the von Hippel-Lindau protein with HIF-1α, subsequently preventing HIF-1α proteasomal degradation (32). Since CoCl2 stabilizes the α subunits of HIFs, the transcription of HIF-targeted genes may be induced by HIFs in spite of the presence of oxygen (4,33). CoCl2 has been successfully used to mimic hypoxia in in vivo and in vitro experimental studies (34). In the present study, a hypoxia model was successfully established through CoCl2 treatment of MCF-7 cells. The present results demonstrated that CoCl2 treatment induces HIF-2α transcription and translation and increases the mRNA and protein expressions of HIF-2α. Additionally, transfection with HIF-2α siRNA inhibited the expression of HIF-2α mRNA and protein, which indicated that the silencing effect of siRNA on HIF-2α was successful. Furthermore, the present experiments revealed that HIF-2α siRNA inhibited breast cancer cell invasion abilities; basement membrane assays reveled that there were a decreased number of invading HIF-2α siRNA transfected MCF-7 cells under hypoxic conditions in vitro compared with control cells. This finding suggests that HIF-2α may be important in MCF-7 cell survival and invasion. These results are similar to a previous study that revealed that HIF-2α promotes tumor progression in Von-Hippel-Lindau-defective renal carcinoma cells (12). By contrast in other tumor types, HIF-2α has an important role as a tumor suppressor; embryonic stem cells are deficient in HIF-2α and display enhanced growth in ovarian tumors (35). In addition, a high-expression of HIF-2α may suppress tumor growth in brain glioma cells (36).

In the present study, in order to verify whether HIF-2α affects MMP-2 expression, siRNA against HIF-2α was used to downregulate the expression of HIF-2α in MCF-7 cells. The results indicated that the expression of MMP-2 mRNA and protein decreased once MCF-7 cells were transfected with HIF-2α siRNA under hypoxic conditions. Collectively, the present findings demonstrate that the regulation of MMP-2 by hypoxia leads to increased invasion of breast cancer cells, which facilitates metastasis.

In conclusion, the present study has demonstrated for the first time, to the best of our knowledge, that HIF-2α is endogenously expressed in eukaryotic cells. In a hypoxia-tolerant tumor cell line (MCF-7) HIF-2α is involved in tumor cell invasion in vitro, which confirms the present author's hypothesis: HIF-2α facilitates cancer cell metastasis in hypoxic environments. Collectively, the present results provide a novel mechanism that HIF-2α signaling is important for cancer development and cancer cell survival by altering the expression of the downstream targets, including MMP-2. Notably, the present study revealed that siRNA targeting of HIF-2α may be a viable approach in the treatment of malignant diseases.

Acknowledgements

The present study was supported by the University Key Teacher Grant from the Ministry of Education of Henan (Zhengzhou, China; grant no. 2012GGJS-136) and Scientific Research Fund of Xinxiang Medical University (Xinxiang, China; grant no. 2014QN113).

References

1 

Bohensky J, Terkhorn SP, Freeman TA, Adams CS, Garcia JA, Shapiro IM and Srinivas V: Regulation of autophagy in human and murine cartilage: Hypoxia-inducible factor 2 suppresses chondrocyte autophagy. Arthritis Rheum. 60:1406–1415. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J and Ratcliffe PJ: Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 284:16767–16775. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Kütscher C, Lampert FM, Kunze M, Markfeld-Erol F, Stark GB and Finkenzeller G: Overexpression of hypoxia-inducible factor-1 alpha improves vasculogenesis-related functions of endothelial progenitor cells. Microvasc Res. 105:85–92. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Rankin EB, Rha J, Unger TL, Wu CH, Shutt HP, Johnson RS, Simon MC, Keith B and Haase VH: Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene. 27:5354–5358. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Copple BL, Bai S and Moon JO: Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic Kupffer cells. Hepatol Res. 40:530–539. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E and Harris AL: Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer. 90:1235–1243. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Liu W, Xin H, Eckert DT, Brown JA and Gnarra JR: Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. Oncogene. 30:21–31. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Zhao S, Jin C, Zhao X, Jin B, Hui L, Zhou W, Niu G and Tao S: Expression and clinical significance of ING4 and HIF-1 alpha in brain astrocytoma. Zhonghua Yi Xue Za Zhi. 95:3533–3536. 2015.(In Chinese). PubMed/NCBI

9 

Burrows N, Babur M, Resch J, Williams KJ and Brabant G: Hypoxia-inducible factor in thyroid carcinoma. J Thyroid Res. 2011:7629052011. View Article : Google Scholar : PubMed/NCBI

10 

Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G and Del Bufalo D: Bcl-2 regulates HIF-1α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One. 5:e117722010. View Article : Google Scholar : PubMed/NCBI

11 

Mardilovich K and Shaw LM: Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion. Cancer Res. 69:8894–8901. 2009.10.1158/0008-5472.CAN-09-1152. View Article : Google Scholar : PubMed/NCBI

12 

Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC and Keith B: HIF-2α deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA. 107:14182–14187. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Florczyk U, Czauderna S, Stachurska A, Tertil M, Nowak W, Kozakowska M, Poellinger L, Jozkowicz A, Loboda A and Dulak J: Opposite effects of HIF-1α and HIF-2α on the regulation of IL-8 expression in endothelial cells. Free Radic Biol Med. 1:1882–1892. 2011. View Article : Google Scholar

15 

Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q and Haase VH: Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 29:4527–4538. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Choi YK, Kim CK, Lee H, Jeoung D, Ha KS, Kwon YG, Kim KW and Kim YM: Carbon monoxide promotes VEGF expression by increasing HIF-1α protein level via two distinct mechanisms, translational activation and stabilization of HIF-1α protein. J Biol Chem. 285:32116–32125. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL and Haase VH: Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 116:3039–3048. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B and Haase VH: Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 117:1068–1077. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Wei K, Piecewicz SM, McGinnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan KX, Kuo D, Yuan J, et al: A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med. 19:1331–1337. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Qiu Y, Zheng H, Sun LH, Peng K, Xiao WD and Yang H: Hypoxia-inducible factor-1 modulates upregulation of mutT homolog-1 in colorectal cancer. World J Gastroenterol. 21:13447–13456. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Fukasawa T, Enomoto A and Miyagawa K: Serine-Threonine Kinase 38 regulates CDC25A stability and the DNA damage-induced G2/M checkpoint. Cell Signal. 27:1569–1575. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Meade ES, Ma YY and Guller S: Role of hypoxia-inducible transcription factors 1α and 2α in the regulation of plasminogen activator inhibitor-1 expression in a human trophoblast cell line. Placenta. 28:1012–1019. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Li N, Wang HX, Zhang A, Ye YP and He GY: KISS-1 inhibits the proliferation and invasion of gastric carcinoma cells. World J Gastroenterol. 18:1827–1833. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Bensellam M, Duvillié B, Rybachuk G, Laybutt DR, Magnan C, Guiot Y, Pouysségur J and Jonas JC: Glucose-induced O2 consumption activates hypoxia inducible factors 1 and 2 in rat insulin-secreting pancreatic beta-cells. PLoS One. 7:e298072012. View Article : Google Scholar : PubMed/NCBI

26 

Jing SW, Wang YD, Kuroda M, Su JW, Sun GG, Liu Q, Cheng YJ and Yang CR: HIF-1α contributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression. Acta Med Okayama. 66:399–407. 2012.PubMed/NCBI

27 

Leonard MO, Howell K, Madden SF, Costello CM, Higgins DG, Taylor CT and McLoughlin P: Hypoxia selectively activates the CREB family of transcription factors in the in vivo lung. Am J Respir Crit Care Med. 178:977–983. 2008. View Article : Google Scholar : PubMed/NCBI

28 

Gordan JD, Bertout JA, Hu CJ, Diehl JA and Simon MC: HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 11:335–347. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Huang KT, Takano EA, Mikeska T, Byrne DJ, Dobrovic A and Fox SB: Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Res Treat. 130:319–329. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Li N, Wang HX, Qin C, Wang XH and Han FY: Relationship between clinicopathological features and HIF-2α in gastric adenocarcinoma. Genet Mol Res. 14:1404–1413. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Xiao H, Gu Z, Wang G and Zhao T: The possible mechanisms underlying the impairment of HIF-1α pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int J Med Sci. 10:1412–1421. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Yokoe S, Nakagawa T, Kojima Y, Higuchi K and Asahi M: Indomethacin-induced intestinal epithelial cell damage is mediated by pVHL activation through the degradation of collagen I and HIF-1α. Biochem Biophys Res Commun. 468:671–676. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Zhu P, Ning Y, Yao L, Chen M and Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res. 29:1242010. View Article : Google Scholar : PubMed/NCBI

34 

Yoo HI, Moon YH and Kim MS: Effects of CoCl2 on multi-lineage differentiation of C3H/10T1/2 mesenchymal stem cells. Korean J Physiol Pharmacol. 20:53–62. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Wang Q, Peng K and He L: Expression of the HIF-2α in epithelial ovarian cancer and clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 39:889–893. 2014.PubMed/NCBI

36 

Anelli V, Gault CR, Cheng AB and Obeid LM: Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem. 283:3365–3375. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Li N, Wang H, Zhang J and Zhao E: Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells. Oncol Lett 11: 3743-3748, 2016.
APA
Li, N., Wang, H., Zhang, J., & Zhao, E. (2016). Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells. Oncology Letters, 11, 3743-3748. https://doi.org/10.3892/ol.2016.4471
MLA
Li, N., Wang, H., Zhang, J., Zhao, E."Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells". Oncology Letters 11.6 (2016): 3743-3748.
Chicago
Li, N., Wang, H., Zhang, J., Zhao, E."Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells". Oncology Letters 11, no. 6 (2016): 3743-3748. https://doi.org/10.3892/ol.2016.4471
Copy and paste a formatted citation
x
Spandidos Publications style
Li N, Wang H, Zhang J and Zhao E: Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells. Oncol Lett 11: 3743-3748, 2016.
APA
Li, N., Wang, H., Zhang, J., & Zhao, E. (2016). Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells. Oncology Letters, 11, 3743-3748. https://doi.org/10.3892/ol.2016.4471
MLA
Li, N., Wang, H., Zhang, J., Zhao, E."Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells". Oncology Letters 11.6 (2016): 3743-3748.
Chicago
Li, N., Wang, H., Zhang, J., Zhao, E."Knockdown of hypoxia inducible factor-2α inhibits cell invasion via the downregulation of MMP-2 expression in breast cancer cells". Oncology Letters 11, no. 6 (2016): 3743-3748. https://doi.org/10.3892/ol.2016.4471
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team